Categories
Health

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is  a   biotech which has been effective vigilantly but unsuccessfully to produce a single therapy, variously called Pro 140, leronlimab, as well as Vyrologix.

In development of this treatment, CytoDyn has cast its net wide and far both geographically and in phrases of prospective indications.

CytoDyn’s inventories of leronlimab are actually building up, whether they will ever be used is actually an open question.

While CYDY  has been dawdling, promote opportunities for leronlimab as being a combination therapy in the curing of multi-drug-resistant HIV are actually closing.

I’m composing my fifteenth CytoDyn (OTCQB:CYDY) report on FintechZoom to celebrate the sale of my past few shares. The 1st CytoDyn post of mine, “CytoDyn: What to be able to Do When It’s Too Good To Be True?”, set out what follows prediction:

Instead I expect it to be a serial disappointer. CEO Pourhassan offered such a highly promotional picture in the Uptick Newswire job interview that I came away with a poor opinion of the business.

Irony of irony, the poor opinion of mine of the business has grown steadily, though the disappointment hasn’t been financial. 2 many years ago CytoDyn was trading <$1.00. On 2/19/20 as I write, it trades at $5.26; the closing transaction of mine was on 2/11/21 > $6.00.

What manner of stock  is it that delivers a > six bagger yet still disappoints? Therein lies the story; permit me to explain.

CytoDyn acquired its much-storied treatment (which I shall mean as leronlimab) back throughout 2012, announced as follows:

CytoDyn Inc…. has completed the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) looking for the CCR5 receptor for your treatment and reduction of HIV, from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is a late Stage II clinical development mAb with demonstrated anti-viral activity in HIV- infected subjects. Today’s payment of $3.5 zillion transfers ownership of the expertise and linked intellectual property from Progenics to CytoDyn, as well as roughly twenty five million mg of majority drug substance…. milestone payments after commencement of a stage III clinical trial ($1.5 huge number of) plus the very first new drug application approval ($five million), as well as royalty payments of five % of net sales after commercialization.

Since that point in time, CytoDyn’s leading nous, Nader Pourhassan [NP] has made this inauspicious acquisition right into a springboard for CytoDyn to acquire a market cap > $3.5 billion. It has done so in premium reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

As opposed to having a pipeline with many indications and numerous therapies, it’s this individual therapies as well as a “broad pipeline of indications” as it puts it. I call such pipelines, “pipedots.” In CytoDyn’s situation it touts the leronlimab of its as a potentially advantageous therapy in dozens of indications.

Its opening banner on its site (below) shows an active organization with diverse interests albeit centered on leronlimab, multiple disease sorts, multiple presentations and multiple publications.

Can all this be smoke and mirrors? That is a question I’ve been asking myself with the really start of the interest of mine in this particular company. Judging by the multiples of thousands of several remarks on listings accessible through Seeking Alpha’s CytoDyn Summary page, I am a lot from alone in this particular question.

CytoDyn is a classic battleground, or even some might say cult stock. Its adherents are fiercely protective of its prospects, quick to label some bad opinions as scurrilous short mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Leave a Reply

Your email address will not be published. Required fields are marked *